AIV Logo AIV Assistant

 Logo Amphastar Pharmaceuticals, Inc. - AMPH 23.34 USD

P/E
13.74
EPS
2.91
P/B
2.90
ROE
25.34
Beta
0.80
Target Price
63.25 USD

23.340 USD

23.340 USD

Daily: +1.66%
Key Metrics

Earnings date: Aug. 5, 2025

P/E: 13.74

EPS: 2.91

Book Value: 13.77

Price to Book: 2.90

Debt/Equity: 93.27

% Insiders: 22.011%

Growth

Revenue Growth: 0.23%

Earnings Growth: 0.62%

Estimates

Forward P/E: 9.04

Forward EPS: 4.42

Target Mean Price: 63.25

 Logo About Amphastar Pharmaceuticals, Inc. - (AMPH)

Country: United States

Sector: Health Care

Website: http://www.amphastar.com

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Exchange Ticker
FRA (Germany) 29A.F
NMS (United States) AMPH
Historical Dividends
Year Total Dividends
2010 0.30 USD
2009 0.30 USD

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion